Stocks in News: Thursday, 15 October 2026

Daily 10:00 AM IST scan. This quick report scans the current Nifty 500 universe (501 constituents) against recent corporate announcements and market headlines from the monitored feeds. Items are grouped by headline tone and are not buy or sell recommendations.

Positive Stocks in News (6)

• JM Financial: Tata Tech shares rally 8% after Q2 results, but Goldman Sachs and JM Financial stay bearish. Here's why. Tata Technologies shares surged after reporting a 4% YoY rise in Q2 net profit to Rs 171 crore. Revenue grew 28% to Rs 1,699 crore, led by a 34% jump in services revenue to Rs 1,356 crore. EBITDA rose 32% to Rs 273 crore, with margins expanding 40 bps to 16.1%. Services revenue grew 4.3% sequentially in constant currency terms to $142 million. (Positive) Source: Economic Times Markets
• Paytm: Paytm shares get new Buy rating after Nomura initiates coverage. 3 reasons behind bullish call. Nomura has initiated coverage on Paytm with a Buy rating and a target price of Rs 2,250, implying an upside of 31%. The brokerage expects EBITDA to grow at a 96% CAGR over FY26-29F, driven by payments, merchant lending, AI-led cost efficiencies and potential UPI MDR revenue. International expansion and enterprise AI product Pi offer additional growth opportunities. (Positive) Source: Economic Times Markets
• Reliance Industries: Reliance Industries shares in focus as Jio IPO sets price band for possibly biggest-ever issue. What shareholders must know. Reliance Industries shares will be in focus after Jio Platforms announced its IPO price band of Rs 1,065-1,119 per share. The Rs 30,213 crore issue includes a shareholder reservation for eligible RIL investors and could become India's largest IPO. Also reported: Reliance Jio IPO: Apply or not? Should you subscribe to issue after launch or wait for listing? What GMP signals?. Reliance Jio IPO: Jio Platforms IPO, which will remain open for subscription till Friday, 23 October, also announced the IPO price band at ₹1,065– ₹1,119 per equity share Also reported: Reliance Jio IPO: Good news for RIL shareholders! Check what the reservation quota is for them. Jio Platforms will launch its IPO from October 21 to 23, 2026, at ₹1,065– ₹1,119 per share. The fresh issue of up t... (Positive) Source: Economic Times Markets
• Biocon: Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch. Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech's patent infringement suit, the New Jersey court dismissed the case at Genentech's request. The details of the settlement agreement remain confidential between the companies involved. Also reported: Biocon clears path for cancer drug launch. Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing legal disputes between the two companies in jurisdictions such as the US and Canada. Under the terms, Biocon can launch Pebrilzo in the EU and UK by early 2027 and in the US by Q3 of 2028. O... (Positive) Source: Economic Times Companies
• IDBI Bank: Cabinet clears way for Watsa's Fairfax's Rs 52,878 crore deal for 60.72% stake in IDBI Bank. Fairfax Financial Holdings will acquire a majority stake of 60.72% in IDBI Bank for ₹52,878 crore. This acquisition marks a significant moment in the government's divestment efforts, as it represents strategic restructuring. The deal aims to strengthen the banking ecosystem and support the government's disinvestment target for the fiscal year. IDBI Bank's financial position has improved significantly, with reduced no... Also reported: Fairfax's IDBI deal premium justified by strategic fit, scale: Analysts. Analysts believe this acquisition holds considerable potential, greatly enhancing Fairfax's branch network and deposit portfolio in India, paving the way for a diversified financial ecosystem. Also reported: Fairfax offers plan to resolve IDBI-CSB ownership overlapping. A merger of the two lend... (Positive) Source: Economic Times Companies
• Hyundai Motor India: Hyundai bets on expansion; hopes to return to No 2 position in PV sales by 2028-29. Hyundai Motor India plans to expand its Talegaon plant to increase production capacity for the domestic market. The company aims to enhance its market share to reclaim the No. 2 position by 2028-29. With an investment of ₹7,000 crore in Maharashtra, Hyundai is focusing on localization and creating new job opportunities. Furthermore, plans to launch 26 new models are expected to strengthen Hyundai's product portfolio. (Positive) Source: Economic Times Companies

Neutral Stocks in News (2)

• Rainbow Childrens Medicare: Rainbow Children's Medicare among 4 stocks that closed crossing above VWAP. Four Nifty 500 stocks closed over 1.5% above their respective VWAPs on October 14, indicating positive trading momentum. (Neutral) Source: Economic Times Markets
• Ceat: CEAT to hike tyre prices by 4-6 pc this quarter amid increased raw material costs. Although the company has raised prices in the last two quarters, it could not fully offset inflation in major raw materials such as rubber and petroleum-based items. This was reflected in its second-quarter earnings, where profit plunged nearly 40 per cent, and margins fell into single digits. (Neutral) Source: Economic Times Companies

Negative Stocks in News (0)

• No matching items in this category at publication time.

Quick Reading Checklist

1. Open the linked source and verify the original exchange filing.
2. Check whether the news is already reflected in the price and volume.
3. Review liquidity, corporate actions, valuation and your stop-loss before trading.

Disclaimer: This automated Stocks in News report is for educational and self-research purposes only. It is not investment advice. A positive headline does not mean a stock should be bought. Verify the original exchange filing, price, liquidity and your own risk limits before trading.